Abstract
Background: Autoantibodies (AAbs) against islet autoantigens (AAgs) are used for type 1 diabetes (T1D) diagnosis and prediction. Islet-specific AAbs usually appear early in life and may fluctuate in terms of number and titer sometimes for over 20 years before T1D develops. Whereas their predictive power is high for pediatric subjects with high genetic risk who rapidly progress to multiple AAb positivity, they are less reliable for children with low genetic risk, single AAb positivity and slow disease progression.
Objective: It is unknown how AAbs develop and whether they are involved in T1D pathogenesis. So far an increase in AAb number seems to only indicate AAg spreading and progression towards clinical T1D. The goal of this review is to shed light on the possible involvement of AAbs in T1D development. Method: We thoroughly review the current literature and discuss possible mechanisms of AAb development and the roles they may play in disease pathogenesis. Results: Genetic and environmental factors instigate changes at the molecular and cellular levels that promote AAb development. Although direct involvement of AAbs in T1D is less clear, autoreactive B cells are clearly involved in various immune and autoimmune responses via antigen presentation, immunoregulation and cytokine production. Conclusion: Our analysis suggests that understanding the mechanisms that lead to islet-specific AAb development and the diabetogenic processes that autoreactive B cells promote may uncover additional biomarkers and therapeutic targets.Keywords: Autoantibodies, type 1 diabetes, prediction, prevention, biomarker, diabetogenesis.
Current Diabetes Reviews
Title:Beta-cell Specific Autoantibodies: Are they Just an Indicator of Type 1 Diabetes?
Volume: 13 Issue: 3
Author(s): Georgia Fousteri*, Elio Ippolito, Rizwan Ahmed and Abdel Rahim A. Hamad
Affiliation:
- Diabetes Research Institute (DRI), IRCCS San Raffaele Scientific Institute, Milan,Italy
Keywords: Autoantibodies, type 1 diabetes, prediction, prevention, biomarker, diabetogenesis.
Abstract: Background: Autoantibodies (AAbs) against islet autoantigens (AAgs) are used for type 1 diabetes (T1D) diagnosis and prediction. Islet-specific AAbs usually appear early in life and may fluctuate in terms of number and titer sometimes for over 20 years before T1D develops. Whereas their predictive power is high for pediatric subjects with high genetic risk who rapidly progress to multiple AAb positivity, they are less reliable for children with low genetic risk, single AAb positivity and slow disease progression.
Objective: It is unknown how AAbs develop and whether they are involved in T1D pathogenesis. So far an increase in AAb number seems to only indicate AAg spreading and progression towards clinical T1D. The goal of this review is to shed light on the possible involvement of AAbs in T1D development. Method: We thoroughly review the current literature and discuss possible mechanisms of AAb development and the roles they may play in disease pathogenesis. Results: Genetic and environmental factors instigate changes at the molecular and cellular levels that promote AAb development. Although direct involvement of AAbs in T1D is less clear, autoreactive B cells are clearly involved in various immune and autoimmune responses via antigen presentation, immunoregulation and cytokine production. Conclusion: Our analysis suggests that understanding the mechanisms that lead to islet-specific AAb development and the diabetogenic processes that autoreactive B cells promote may uncover additional biomarkers and therapeutic targets.Export Options
About this article
Cite this article as:
Fousteri Georgia*, Ippolito Elio, Ahmed Rizwan and A. Hamad Rahim Abdel, Beta-cell Specific Autoantibodies: Are they Just an Indicator of Type 1 Diabetes?, Current Diabetes Reviews 2017; 13 (3) . https://dx.doi.org/10.2174/1573399812666160427104157
DOI https://dx.doi.org/10.2174/1573399812666160427104157 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
Call for Papers in Thematic Issues
Advancing Diabetic Wound Healing: Mechanisms and Interventions
In recent years, diabetic wounds have become a global health concern with the increase in the incidence of diabetes. Diabetic wounds are a kind of chronic and refractory ulcer. It is generally due to the microcirculatory disturbances and the reduced levels of endogenous growth factors. Delayed cutaneous wound healing is ...read more
Oxidative and inflammatory responses in the development of secondary diabetic complications
Diabetes, along with its associated secondary complications, represents a significant global health challenge, contributing significantly to morbidity and mortality. Unhealthy lifestyle habits, reduced physical activity, environmental pollutants, and stress are pivotal factors in the onset of diabetes, particularly type-2 diabetes. Poorly managed hyperglycemia can lead to various complications, including neuropathy, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Diabetes Case Identification Methods Applied to Electronic Medical Record Systems: Their Use in HIV-Infected Patients
Current HIV Research Treatment Strategies Against Diabetic Foot Ulcer: Success so Far and the Road Ahead
Current Diabetes Reviews Non-glycemic Adverse Effects of Insulin
Current Diabetes Reviews Brittle Type 1 Diabetes Mellitus
Current Medicinal Chemistry Hyperglycemic Hyperosmolar State Associated with Low-Dose Quetiapine Treatment in a Patient with Bipolar Disorder
Current Drug Safety Recent Developments of C-Aryl Glucoside SGLT2 Inhibitors
Current Medicinal Chemistry Applications and Limitations of Genetically Modified Mouse Models in Drug Discovery and Development
Current Drug Metabolism Polyphenols: Potential Future Arsenals in the Treatment of Diabetes
Current Pharmaceutical Design Medicinal Plants for Diabetes Treatment During Pregnancy
Current Medicinal Chemistry Diabetes Gene Therapy: Potential and Challenges
Current Gene Therapy Challenges for Gene Therapy of Type 1 Diabetes
Current Gene Therapy Role of the Insulin Receptor Variant Forms in Human Metabolic Disorders
Current Genomics Addressing Unmet Medical Needs in Type 1 Diabetes: A Review of Drugs Under Development
Current Diabetes Reviews Continuous Subcutaneous Insulin Infusion (CSII) in Diabetic Pregnancy: A Review
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Therapeutic Challenges in Neuroendocrine Tumors
Anti-Cancer Agents in Medicinal Chemistry EDITORIAL (Thematic Issue: Retinal Neurodegeneration in the Course of Diabetes: Neuroprotection as a Potential Treatment Target)
Current Neuropharmacology Activated T Lymphocytes in Type 2 Diabetes: Implications From in Vitro Studies
Current Drug Targets Optic Nerve and Cerebral Edema in the Course of Diabetic Ketoacidosis
Current Neuropharmacology Surgical Complications of Hyperglycaemia
Current Diabetes Reviews The Interactions Between Diabetes Mellitus and Myelodysplastic Syndromes: Current State of Evidence and Future Directions
Current Diabetes Reviews